Novel rapid-acting sublingual nicotine tablet as a cigarette substitution strategy

Abstract

Current nicotine replacement products provide a much slower onset of nicotine delivery than cigarettes, and hence are only marginally effective at supplanting cigarette smoking. Therefore, more effective forms of nicotine replacement are needed. This initial investigation characterized the pharmacokinetic (PK) and subjective effects of a novel sublingual (SL) nicotine tablet designed to deliver nicotine more rapidly to the bloodstream of smokers. Study 1 (N = 6) characterized the pharmacokinetics of a 2mg nicotine SL tablet in comparison to an FDA-approved, marketed 2mg nicotine lozenge. Study 2 (N = 24) assessed subjective responses of smokers to a single use of a 1mg and 2mg SL tablet. Study 1 found that the time to maximum blood nicotine concentrations was significantly shorter for the SL tablet (14min) than for the lozenge (82min), and the initial rate of nicotine absorption was higher (0.4ng/mL*min vs. 0.0ng/mL*min), supporting the hypothesis that the SL tablet delivered nicotine more rapidly. Study 2 found that participants reported immediate relief of nicotine withdrawal symptoms after tablet administration, and craving reduction after the 2mg tablet approached the degree reported for their usual brands of cigarettes (4.2 vs. 4.6 on a 7-point scale). Other subjective responses showed the tablet to be an appealing alternative to smoking. The novel SL tablet studied shows promise as a nicotine substitution strategy for tobacco harm reduction and smoking cessation treatment. Additional studies are warranted to further investigate the potential of this new approach.